Our system can take your drug discovery timeline from years to months.
Click to learn more.
We can save most companies around 40% on testing their vaccine candidates. Our tests can confirm negative immunigenocity with a fraction of the trials used in current testing.
Services can be performed at our labs or in yours, or with approved CROs.
NanoCliq’s technology has been vested by scientists at two of the world’s leading research institutions.
World's First leishmanias vaccine
the nQ Platform
NanoCliq's vaccine for Leishmaniasis is built on the patent-pending nQ nanoparticle platform conjugated with a specialized carbohydrate signature for Leishmaniasis. Studies conducted with our collaborating lab in Brazil have demonstrated protection from the disease in inoculated laboratory animals. The company is currently raising funds to complete FDA work and begin human trials.
of contracting Leishmania each year
of Leishmaniasis Annually
The Leishmania vaccine was prototyped and built in less than a year.
Unlike common expensive chicken-egg vaccines, nQ vaccines are produced by engineered bacteria.
Dr. MG Finn
NY Daily With the U.S. Centers for Disease Control warning that 700,000 people on the island of Puerto Rico will contract the Zika virus by year’s end, America must mount a public health campaign. New CDC Laboratory Test for Zika Virus Authorized for Emergency Use by FDA In response to a request from the Read more about 20% of Puerto Ricans expected to Contract Zika[…]
Jimmy Carter announced Sunday that he no longer needs treatment for cancer, less than seven months after revealing he had been diagnosed with melanoma that spread to his brain. ABC News Article
Courtesy: https://twitter.com/hashtag/nanocliq Read more here: Georgia Bio 2015 For more than 13 years, Georgia Bio has presented Georgia’s premier bioscience and medtech conference welcoming 600+ CEOs, senior executives, scientists and public policy officials from Georgia and across the nation. NanoCliq was honored to be the opening speakers for the conference.